COVID19 Vaccine
DCGI approves Phase II+III trials of Oxford University vaccine by Serum Institute
New Delhi: The Drugs Controller General of India (DCGI) has given approval to Serum Institute of India, Pune to conduct Phase II+III clinical trials of Oxford University-Astra Zeneca COVID-19 vaccine (COVISHIELD) in India. This will hasten the development of the COVID-19 vaccine.
India continues to improve the Case Fatality Rate (CFR), and maintain its global position of having one of the lowest COVID fatalities rates.
With a further fall, the current CFR touched 2.11% today.
This is the outcome of the well conceived and effectively implemented strategy of "Test, Track and Treat" which has guided the COVID management in the country.
The management strategy of COVID-19 also focuses on early detection and isolation of cases with seamless patient management and prioritising care of the high-risk population using field health care workers leading to increase in recoveries across the country.
India has seen more than 40,574 patients recovered in the last 24 hours.
This takes the total recoveries to 11,86,203 and Recovery Rate to 65.77% amongst COVID-19 patients.
With improving daily recovery number, the gap between the recovered cases & the active cases has increased to more than 6 lakh.
Presently, it is 6,06,846.
This means the actual active case load is 5,79,357 and all are under medical supervision.
Support Our Journalism
We cannot do without you.. your contribution supports unbiased journalism
IBNS is not driven by any ism- not wokeism, not racism, not skewed secularism, not hyper right-wing or left liberal ideals, nor by any hardline religious beliefs or hyper nationalism. We want to serve you good old objective news, as they are. We do not judge or preach. We let people decide for themselves. We only try to present factual and well-sourced news.
Support objective journalism for a small contribution.
